[{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"57e9cf07-fbd3-4b60-b000-b857b664ab20","acronym":"ATARI","url":"https://clinicaltrials.gov/study/NCT04065269","created_at":"2021-01-18T19:55:05.811Z","updated_at":"2025-02-25T15:08:44.072Z","phase":"Phase 2","brief_title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","source_id_and_acronym":"NCT04065269 - ATARI","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-07-11"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"},{"id":"79ef0e88-111d-46b4-b454-13193bb2c7c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05002868","created_at":"2021-08-12T13:54:30.231Z","updated_at":"2024-07-02T16:35:05.010Z","phase":"Phase 1","brief_title":"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors","source_id_and_acronym":"NCT05002868","lead_sponsor":"Rhizen Pharmaceuticals SA","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RP12146"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 04/25/2024","primary_completion_date":" 04/25/2024","study_txt":" Completion: 04/25/2024","study_completion_date":" 04/25/2024","last_update_posted":"2024-05-08"},{"id":"f6337414-9975-408c-9a77-c574d3607574","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078670","created_at":"2023-10-12T22:13:53.034Z","updated_at":"2024-07-02T16:35:33.749Z","phase":"Phase 1/2","brief_title":"PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078670","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" PD-L1 • BRCA1 • BRCA2 • CHEK2","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-10-12"}]